Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

633
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

565
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
565
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Delphi survey of patients and clinicians on a unified and stratified approach to managing GCA-PMR spectrum disease.

Rheumatology (Oxford, England)·2026
Same author

A conceptual framework for a RA probability score integrating classification criteria and point-of-care ultrasound in early arthritis.

Rheumatology (Oxford, England)·2026
Same author

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

The New England journal of medicine·2026
Same author

Evaluating machine learning tools to assist title and abstract screening in systematic literature reviews: a report based on the EULAR RA Management Recommendations Task Force.

Annals of the rheumatic diseases·2026
Same author

Risk factors for recurrent falls in midlife: a prospective cohort study using data from the Health and Employment After Fifty (HEAF) study.

BMJ open·2026
Same author

A national survey report to facilitate rheumatology ultrasound curriculum proposal.

Rheumatology (Oxford, England)·2026
Same journal

Vaccination practice and safety in children with special health care needs: A retrospective study of 1278 children.

Human vaccines & immunotherapeutics·2026
Same journal

Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.

Human vaccines & immunotherapeutics·2026
Same journal

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation.

Human vaccines & immunotherapeutics·2026
Same journal

Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.

Human vaccines & immunotherapeutics·2026
Same journal

Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.

Human vaccines & immunotherapeutics·2026
Same journal

Determinants of HPV vaccination acceptance among young adult women in Japan's catch-up generation: A cross-sectional study.

Human vaccines & immunotherapeutics·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Tocilizumab (Actemra).

Martin Sheppard1, Faidra Laskou1, Philip P Stapleton1

  • 1a Southend University Hospital NHS Foundation Trust , Westcliff on Sea , UK.

Human Vaccines & Immunotherapeutics
|August 26, 2017
PubMed
Summary
This summary is machine-generated.

Tocilizumab (TCZ) is an interleukin-6 receptor (IL-6R) inhibitor used for rheumatoid arthritis and juvenile idiopathic arthritis. This review covers its development, efficacy, and future potential in treating inflammatory conditions like giant cell arteritis.

Keywords:
giant cell arteritisinterleukin-6monoclonal antibodyrheumatoid arthritistocilizumabvasculitis

More Related Videos

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.7K
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.1K

Related Experiment Videos

Last Updated: Feb 24, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.7K
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.1K

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in various autoimmune diseases.
  • Tocilizumab (TCZ) is a monoclonal antibody targeting the IL-6 receptor (IL-6R).
  • TCZ is approved for treating rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (sJIA), and polyarticular juvenile idiopathic arthritis (pJIA).

Purpose of the Study:

  • To provide a comprehensive overview of tocilizumab (TCZ).
  • To review the discovery of IL-6 and the development of TCZ.
  • To explore the current and future applications of TCZ in treating inflammatory and autoimmune conditions.

Main Methods:

  • Literature review of IL-6 discovery, TCZ development, manufacturing, and clinical trials.
  • Comparative analysis of TCZ with other biologics for RA, sJIA, and pJIA.
  • Exploration of emerging therapeutic roles for IL-6 blockade in conditions like GCA, PMR, and LVV.

Main Results:

  • TCZ has demonstrated efficacy and safety in treating RA, sJIA, and pJIA.
  • Comparative analysis highlights TCZ's advantages and disadvantages against other biologics.
  • Emerging evidence suggests TCZ's potential in treating giant cell arteritis (GCA), polymyalgia rheumatica (PMR), and large vessel vasculitis (LVV).

Conclusions:

  • Tocilizumab is an effective biologic therapy for established indications.
  • IL-6 blockade represents a promising therapeutic strategy for various inflammatory diseases.
  • Further research is warranted to fully elucidate the role of TCZ in GCA, PMR, and LVV.